导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.02% | 2822/4773 |
| 近一周 | -2.18% | 1411/5462 |
| 近一月 | -0.18% | 761/5421 |
| 近一季 | -1.52% | 1019/5209 |
| 近半年 | -8.70% | 3383/4920 |
| 近一年 | 3.36% | 1944/4366 |
| 近两年 | 37.65% | 1989/2954 |
| 近三年 | 27.97% | 1139/2253 |
| 成立以来 | 89.97% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
5.32% 403/4961 |
-12.51% 4409/5312 |
- - |
- - |
| 2025 | 15.61% 2527/4813 |
-1.16% 2597/3635 |
5.63% 559/4076 |
3.97% 3709/4524 |
6.51% 360/4813 |
| 2024 | 13.34% 1150/3463 |
6.15% 309/2808 |
1.28% 485/3014 |
7.54% 2811/3129 |
-1.98% 1913/3463 |
| 2023 | 12.24% 62/2656 |
6.92% 630/2280 |
-0.02% 354/2385 |
5.33% 91/2515 |
-0.31% 199/2655 |
| 2022 | -4.80% 108/2207 |
1.69% 96/1919 |
-2.02% 1764/2016 |
-3.95% 46/2113 |
-0.52% 1619/2208 |
| 2021 | 23.23% 132/1822 |
7.01% 85/1255 |
0.25% 1106/1330 |
10.96% 116/1466 |
3.52% 425/1822 |
| 2020 | 9.04% 849/1250 |
-8.54% 620/1028 |
6.63% 857/1067 |
9.99% 599/1164 |
1.65% 1020/1184 |
| 2019 | 18.75% 678/1092 |
24.63% 501/739 |
-7.91% 571/788 |
-4.35% 766/850 |
8.16% 345/918 |
| 2018 | -21.19% 207/834 |
- - |
-7.55% 169/631 |
-5.17% 366/660 |
-8.08% 79/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华宝标普中国A股红利机会ETF联接C VS. 长安沪深300非周期A(740101) |